BIIBCongressional Stock Trades
Biogen Inc. Common Stock
Biological Products, (No Diagnostic Substances)
Congressional stock trades in Biogen Inc. Common Stock (BIIB) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.
Total Trades
12
Politicians Trading
6
Last Traded
Sep 24, 2026
Trading History
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Maria Elvira SalazarR | Oct 7, 2026 | Sep 24, 2026 | Sell | $1,001 - $15,000 | +10.01% |
| Kevin HernR | Sep 1, 2026 | Aug 18, 2026 | Sell | $1,001 - $15,000 | +17.15% |
| Maria Elvira SalazarR | Jul 7, 2026 | Jun 2, 2026 | Sell | $15,001 - $50,000 | +31.87% |
| Robert BresnahanR | May 8, 2025 | Apr 8, 2025 | Sell | $1,001 - $15,000 | +118.33% |
Price History
About Biogen Inc. Common Stock
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
6 members of Congress have disclosed 12 trades in Biogen Inc. Common Stock (BIIB). Most active: Ro Khanna (3), Robert Bresnahan (3), Gilbert Ray Cisneros, Jr. (2).
Across all disclosures, members of Congress reported 6 purchases and 6 sales of Biogen Inc. Common Stock (BIIB). The most recent trade was on Sep 24, 2026.
Gilbert Ray Cisneros, Jr. disclosed buying Biogen Inc. Common Stock (BIIB) on Jun 5, 2026, valued at $1,001 - $15,000.
Maria Elvira Salazar disclosed selling Biogen Inc. Common Stock (BIIB) on Sep 24, 2026, valued at $1,001 - $15,000.
From House and Senate periodic transaction reports filed under the STOCK Act. Members of Congress must disclose trades within 45 days, and amounts are reported as ranges, not exact values.